CRISPR Therapeutics AG (CRSP) Stock Analysis

CRISPR Therapeutics AG (CRSP) Reports Q3 Loss, Tops Revenue Estimates

Mon, November 2, 2026 at 9:55 PM UTC 2 min read

CRISPR Therapeutics AG (CRSP) reported a Q3 loss of $1.15 per share, slightly worse than the Zacks Consensus Estimate of a $1.06 loss, but exceeded revenue expectations with $12.67 million, surpassing estimates by 27.39%. The company has struggled with earnings surprises, surpassing consensus EPS estimates only once in the last four quarters, and its shares have declined about 2% year-to-date, underperforming the S&P 500's 10.7% gain. The stock currently holds a Zacks Rank #3 (Hold).

Read full article →

Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know

Fri, October 23, 2026 at 12:00 PM UTC 2 min read

CRISPR Therapeutics AG (CRSP) has seen a surge in investor interest recently, driven by advancements in its gene-editing technology and promising clinical trial results. This heightened attention could lead to increased volatility in the stock price, as investors weigh the potential for significant breakthroughs against the inherent risks of biotech investments. Staying informed about CRSP's developments is crucial for investors looking to capitalize on its growth potential in the rapidly evolving biotech sector.

Read full article →